News & Updates

Long-term survival benefits with tebentafusp persist in previously untreated HLA-A∗02:01-positive patients with unresectable or metastatic uveal melanoma (mUM), as shown in the longest survival follow-up of a phase III trial.

First-line treatment with lorlatinib demonstrates long-term survival benefits in patients with advanced anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC), as shown in the 7-year update from the phase III CROWN study.

Four-year updates from the CHIEF study show a durable survival benefit with atezolizumab plus bevacizumab in individuals with advanced hepatocellular carcinoma (HCC).

According to an outpatient surveillance study in Hong Kong, minimally invasive nose-only swabs achieved high agreement with joint nose and throat swabs (NTS) for reverse transcription polymerase chain reaction (RT-qPCR) detection of influenza and SARS-CoV-2, thus presenting a viable alternative specimen type for supervised respiratory virus testing.

A real-world study presented at ESMO GI 2026 shows that pembrolizumab immunotherapy and a combination regimen of encorafenib and cetuximab are associated with meaningful survival benefits in BRAF-mutant metastatic colorectal cancer (CRC).